Elucid raises $55 million to scale AI-powered heart disease diagnostics

Elucid, a Boston-based MedTech company building AI software that reads CT scans for signs of cardiovascular risk, has closed a $55 million Series D round. The raise was oversubscribed, and it brings the company’s total funding to around $185 million.

“Analogous to oncology’s shift from population-based, one-size treatment, Elucid is applying AI to integrate anatomy, biology, and physiology to bring personalized treatment to coronary artery disease management. Physician feedback indicating that our current platform can uniquely lead to better care decisions fuels our mission to predict and personalize the prevention of heart attacks and strokes,” said Kelly Huang, PhD, chief executive officer of Elucid.

Why this round stands out

The round pulled in a new strategic backer: a large, publicly traded MedTech company. That makes four publicly traded strategics now backing Elucid, which is a notable vote of confidence from an industry that doesn’t hand those out lightly. IAG Capital Partners and Elevage Medical Technologies, a platform under Patient Square Capital, also took part.

What Elucid actually does

Most heart attack and stroke risk gets estimated using population-level data, things like age, cholesterol, and family history. Elucid’s software instead looks directly at a patient’s own CT angiography scan and pulls out details about plaque type, plaque volume, and vessel anatomy that a radiologist wouldn’t otherwise measure.
Its main product, Plaque-IQ, already has FDA clearance. It’s currently the only non-invasive tool validated against actual tissue samples that can identify the specific plaque type most associated with heart attacks.

The next piece: FFR-CT

Elucid is now waiting on FDA review for a second product, BioIntegrated FFR-CT, which estimates blood flow restriction in coronary arteries from the same CT scan. That’s normally something doctors check through an invasive catheter procedure. If cleared, Elucid wants to pair it with Plaque-IQ so physicians get plaque biology, anatomy, and blood flow data in one read, instead of ordering separate tests.

Where the money is going

According to the company, the funding will go toward:

• Rolling out its platform commercially, including FFR-CT and Plaque-IQ
• Continued AI research and development
• Larger clinical studies to build out the evidence base

The bigger picture

Elucid is betting that cardiology is headed the same way oncology did, toward decisions based on a patient’s own biology rather than a statistical risk score, and that physicians will increasingly want imaging tools that show them what’s actually happening inside a patient’s arteries.

Whether that bet pays off will depend a lot on what happens with FFR-CT’s FDA review and how quickly hospitals and cardiology practices adopt the technology once it’s cleared.

Want to know what’s next in cardiovascular innovation?

Elucid’s raise is a signal of where cardiovascular technology is headed next. For a deeper look at the broader shift underway, the panel “The Cardiovascular Platform Race: PFA, Structural Heart, Imaging and Robotics” will take a closer look at MedTech World Europe | Malta 2026.

Taking place from 11 to 13 November on the UNESCO-listed island of Malta, MedTech World Europe | Malta 2026 is set to be MedTech World’s biggest conference yet, running two stages in parallel. The event brings together healthcare leaders, innovators, investors, and startups from across the global MedTech community to explore the technologies and ideas influencing the next chapter of healthcare.

Book your ticket to join MedTech World Europe | Malta 2026 and connect with the people driving innovation across the sector.